These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25744866)

  • 21. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy.
    Dishop MK; Warner BW; Dehner LP; Kriss VM; Greenwood MF; Geil JD; Moscow JA
    J Pediatr Hematol Oncol; 2003 Feb; 25(2):153-8. PubMed ID: 12571469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
    Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
    Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
    Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
    Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "How long does crizotinib work? a rare case of recurrent inflammatory myofibroblastic tumor".
    Albayrak HC; Gürler F; Sütçüoğlu O; Akyürek N; Özet A
    Anticancer Drugs; 2022 Jan; 33(1):109-111. PubMed ID: 34261914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
    Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
    J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
    [No Abstract]   [Full Text] [Related]  

  • 33. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
    Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.
    Liu Q; Wei J; Liu X; Wang J
    Medicine (Baltimore); 2019 Dec; 98(52):e18414. PubMed ID: 31876714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-abdominal inflammatory myofibroblastic tumours in children--a report of three cases in 3 years.
    Gopal M; Tan YW; Wood K; Barrett AM; Hosie GP
    Eur J Pediatr Surg; 2012 Jun; 22(3):254-6. PubMed ID: 22576303
    [No Abstract]   [Full Text] [Related]  

  • 38. A cutaneous inflammatory myofibroblastic tumour with ALK rearrangement in the upper extremity.
    Cantile M; Aquino G; Franco R; Marra L; Gallo M; De Chiara A
    Pathology; 2014 Oct; 46(6):575-6. PubMed ID: 25158817
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.
    Kerner GS; Koole MJ; Bongaerts AH; Pruim J; Groen HJ;
    PLoS One; 2016; 11(5):e0149955. PubMed ID: 27137772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.